Cart is empty Patients with the genetic disorder hemophilia A receive factor VIII protein replacement treatments to replenish this clotting protein in their blood, thus preventing dangerous bleeding. Unfortunately, about 30% of these patients develop antibodies against the treatment and until now, despite more than 80 years of clinical experience with this complication, little has been known about its mechanism.
Leave A Comment